Skip to main content
. 2022 Jun 29;58(7):872. doi: 10.3390/medicina58070872

Table 2.

TTF average by diabetes presence and age in different lines of chemotherapy.

Age (Years) ≤29 30–39 40–49 50–59 60–69 70–79 ≥80
Fluoropyrimidine lines of chemotherapy
DM+ (days) - - 109 118 150 90 52
DM− (days) 66 118 124 119 127 132 123
Oxaliplatin lines of chemotherapy
DM+ (days) - - 23 95 142 77 -
DM− (days) 144 161 129 101 93 99 70
Irinotecan lines of chemotherapy
DM+ (days) - - 200 157 176 103 81
DM− (days) 28 90 120 119 129 150 131
Bevacizumab/Aflibercept lines of chemotherapy
DM+ (days) - - 196 81 140 103 -
DM− (days) 42 159 178 171 178 162 88
Cetuximab/Panitumumab lines of chemotherapy
DM+ (days) - - 31 137 239 215 78
DM− (days) 64 129 134 107 171 140 100
HHS Vulnerability Disclosure